Log in

Galmed Pharmaceuticals Stock Price, News & Analysis (NASDAQ:GLMD)

-0.03 (-0.76 %)
(As of 10/18/2019 04:00 PM ET)
Today's Range
Now: $3.93
50-Day Range
MA: $4.61
52-Week Range
Now: $3.93
Volume79,639 shs
Average Volume89,929 shs
Market Capitalization$82.61 million
P/E RatioN/A
Dividend YieldN/A
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company is develops Aramchol, an oral therapy, which is completed ARREST Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:GLMD



Sales & Book Value

Annual Sales$2.04 million
Book Value$4.18 per share


Net Income$-9,860,000.00


Market Cap$82.61 million
Next Earnings Date11/4/2019 (Estimated)

Receive GLMD News and Ratings via Email

Sign-up to receive the latest news and ratings for GLMD and its competitors with MarketBeat's FREE daily newsletter.

Galmed Pharmaceuticals (NASDAQ:GLMD) Frequently Asked Questions

What is Galmed Pharmaceuticals' stock symbol?

Galmed Pharmaceuticals trades on the NASDAQ under the ticker symbol "GLMD."

How were Galmed Pharmaceuticals' earnings last quarter?

Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) announced its quarterly earnings data on Monday, August, 5th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.24) by $0.04. View Galmed Pharmaceuticals' Earnings History.

When is Galmed Pharmaceuticals' next earnings date?

Galmed Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, November 4th 2019. View Earnings Estimates for Galmed Pharmaceuticals.

What price target have analysts set for GLMD?

5 Wall Street analysts have issued twelve-month price objectives for Galmed Pharmaceuticals' shares. Their forecasts range from $20.00 to $59.00. On average, they expect Galmed Pharmaceuticals' share price to reach $32.00 in the next year. This suggests a possible upside of 714.2% from the stock's current price. View Analyst Price Targets for Galmed Pharmaceuticals.

What is the consensus analysts' recommendation for Galmed Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galmed Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Galmed Pharmaceuticals.

What are Wall Street analysts saying about Galmed Pharmaceuticals stock?

Here are some recent quotes from research analysts about Galmed Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing therapies for liver diseases and gallstones. Galmed Pharmaceuticals Ltd. is based in Tel Aviv, Israel. " (10/16/2019)
  • 2. Maxim Group analysts commented, "Galmed reported 2Q19 with a net loss of ($4.2M) and ended the period with $83.6M in cash." (8/6/2019)
  • 3. HC Wainwright analysts commented, "We maintain our Buy rating of ATEC and raise our 12-month price target to $6.00 per share, up from $4.00. We derive our price target based on: (1) an EV-to-sales multiple analysis assuming 10% discount rate and using a 3.0x multiple on projected 2027 sales of $455M; and (2) a discounted cash flow analysis using the projected free cash flow to the firm through 2027 and assuming a 10% discount rate and a 3% terminal growth rate. Using the average of the two methods, we arrive at a 12-month price target of $5.80 per share, which we round to $6.00." (8/6/2019)
  • 4. Cantor Fitzgerald analysts commented, ": We reiterate our OW rating and $59 12-month PT on Galmed Pharmaceuticals following earnings from 4Q18/2018. The company announced plans to have an end-of-Phase 2b meeting with the FDA during March, with the goal of initiating the Phase 3 ARMOR study in late-2Q19/early-3Q19. Minutes from this meeting and finalized Phase 3 trial design plans could be important data points in 2019. Additionally, Galmed will present a poster on Aramchol improvement in liver glucose homeostasis in NASH at EASL on 4/13 (link)." (3/13/2019)

Has Galmed Pharmaceuticals been receiving favorable news coverage?

Media stories about GLMD stock have trended somewhat negative this week, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Galmed Pharmaceuticals earned a media sentiment score of -1.5 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Galmed Pharmaceuticals.

Are investors shorting Galmed Pharmaceuticals?

Galmed Pharmaceuticals saw a drop in short interest in September. As of September 30th, there was short interest totalling 372,200 shares, a drop of 6.4% from the August 30th total of 397,500 shares. Based on an average daily trading volume, of 76,300 shares, the short-interest ratio is currently 4.9 days. Currently, 2.5% of the company's stock are short sold. View Galmed Pharmaceuticals' Current Options Chain.

Who are some of Galmed Pharmaceuticals' key competitors?

What other stocks do shareholders of Galmed Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Galmed Pharmaceuticals investors own include Rite Aid (RAD), Opko Health (OPK), Micron Technology (MU), NVIDIA (NVDA), Verastem (VSTM), Exelixis (EXEL), Immunomedics (IMMU), Viking Therapeutics (VKTX), Conatus Pharmaceuticals (CNAT) and Corbus Pharmaceuticals (CRBP).

Who are Galmed Pharmaceuticals' key executives?

Galmed Pharmaceuticals' management team includes the folowing people:
  • Mr. Allen Baharaff, Chairman, CEO & Pres (Age 54)
  • Mr. Yohai Stenzler, CFO & Controller (Age 36)
  • Mr. Guy Nehemya, Chief Operating Officer (Age 34)
  • Dr. Liat Hayardeny, Chief Scientific Officer (Age 52)
  • Dr. Tali Gorfine, Chief Medical Officer (Age 49)

How do I buy shares of Galmed Pharmaceuticals?

Shares of GLMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Galmed Pharmaceuticals' stock price today?

One share of GLMD stock can currently be purchased for approximately $3.93.

How big of a company is Galmed Pharmaceuticals?

Galmed Pharmaceuticals has a market capitalization of $82.61 million and generates $2.04 million in revenue each year. The biopharmaceutical company earns $-9,860,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis. Galmed Pharmaceuticals employs 17 workers across the globe.View Additional Information About Galmed Pharmaceuticals.

What is Galmed Pharmaceuticals' official website?

The official website for Galmed Pharmaceuticals is http://www.galmedpharma.com/.

How can I contact Galmed Pharmaceuticals?

Galmed Pharmaceuticals' mailing address is 16 TIOMKIN STREET, TEL AVIV L3, 6578317. The biopharmaceutical company can be reached via phone at 972-3693-8448.

MarketBeat Community Rating for Galmed Pharmaceuticals (NASDAQ GLMD)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  375 (Vote Outperform)
Underperform Votes:  197 (Vote Underperform)
Total Votes:  572
MarketBeat's community ratings are surveys of what our community members think about Galmed Pharmaceuticals and other stocks. Vote "Outperform" if you believe GLMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GLMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/19/2019 by MarketBeat.com Staff

Featured Article: Buyback

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel